Key result
Baseline RV dilatation predicts ~185% higher 2-year mortality after TTVr.
Why the study?
Recent ESC/EACTS guidelines proposed adjusted reference values for RV size and function, but their predictive value in patients undergoing transcatheter tricuspid valve repair was unknown.
Do baseline right ventricular dilatation and dysfunction thresholds predict 2-year survival in patients undergoing transcatheter tricuspid valve repair?
Cohort (n=651)
Yes
Do baseline right ventricular dilatation and dysfunction thresholds predict 2-year survival in patients undergoing transcatheter tricuspid valve repair?
Hazard Ratio: 2.85 (95% CI 1.41–5.76)
p-value: p=<0.01
Baseline right ventricular adverse remodeling strongly predicts survival after transcatheter tricuspid valve repair, but achieving effective tricuspid regurgitation reduction can attenuate this risk.
RV thresholds aid risk stratification in TTVr candidates; leaves open prospective validation before guiding decisions.
Background Tricuspid regurgitation (TR) and right ventricular (RV) remodelling are closely related. Recent ESC/EACTS guidelines on valvular heart disease propose adjusted reference values for RV size and function. Aims To determine the predictive value of the proposed RV dilatation and dysfunction thresholds in a real-world interventional cohort. Methods and Results Echocardiographic thresholds were evaluated retrospectively in 651 patients, who underwent transcatheter tricuspid valve repair (TTVr) at two tertiary centres. The primary endpoint was 2-year survival (Kaplan–Meier estimate: 78.6% [74.9–81.9]). RV strain was the most frequent marker of dysfunction at baseline (FWS <23% in 80.3%, GLS <21% in 88.4%). Proposed cut-offs for RV basal (>24 mm/m2), mid (>21 mm/m2), and tricuspid annular (TA) diameters (>21 mm/m2) were associated with survival (p=0.04, <0.01, and <0.01). TAPSE <17 mm was not (p=0.24), whereas TDI s’ <10 cm/s and FAC ≤35% were associated with survival (p=0.04; 0.01). Severe RV dysfunction (FWS <11% or GLS <9%) was associated with survival (p<0.01; 0.02). In multivariable analysis, TA >21 mm/m2 (HR 2.85 [1.41–5.76]; p<0.01) and FWS <11% (HR 1.91 [1.07–3.38]; p=0.03) independently predicted survival. Mortality risk increased for each additional pathological parameter (HR per parameter 1.33 [1.14–1.57]; p <0.01). After effective TR reduction (residual TR <I; n=341, 52%), no RV cut-off remained associated with survival. Conclusions TTVr is often performed at an advanced disease stage, and adverse RV remodelling is strongly associated with survival. Nevertheless, effective TR reduction attenuated this prognostic value.
No takes yet. Share an insight, caveat, or question.
Althoff et al. (2026) conducted a cohort in Tricuspid regurgitation (n=651). Baseline right ventricular dilatation (tricuspid annular diameter >21 mm/m2) vs. Patients without right ventricular dilatation was evaluated on 2-year survival (HR 2.85, 95% CI 1.41-5.76, p=<0.01). Baseline right ventricular dilatation (tricuspid annular diameter >21 mm/m2) independently predicted worse 2-year survival after transcatheter tricuspid valve repair (HR 2.85; 95% CI 1.41-5.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: